Scientists, researchers, academics and global health leaders from around the world will meet at the North Carolina Biotechnology Center Friday, June 27 from 2 to 4 p.m. to discuss ways to tackle human African trypanosomiasis (HAT), or sleeping sickness, commonly found in sub-Saharan Africa.
RTP-based SCYNEXIS is teaming with African scientists and nonprofit partnerships to tackle the disease.
The briefing is hosted by Drugs for Neglected Diseases Initiative (DNDi), a nonprofit pharmaceutical organization working to develop new drugs for neglected tropical diseases. It's one of a number of events showcasing the opening of DNDi's North American regional office in New York.
Experts will be available for interviews and to discuss the issue. Keynote speakers include: Dr. Marcel Tanner, director, Swiss Tropical Institute, chair DNDi board; Dr. Bernard Pecoul, executive director, DNDi; Dr. Yves J. Ribeill, president and CEO, SCYNEXIS, Inc.; Dr. Dawson Mbulamberi, assistant commissioner, Ministry of Health, Uganda; and Dr. Monique Wasunna, acting director, Kenya Medical Research Institute (KEMRI); head, DNDi Africa.
The event is open to the public.
